Dr Nima Nabavizadeh talks to ecancer at ESMO 2025 about data he presented.

The PATHFINDER II study evaluated the 'Galleri' multi-cancer early detection (MCED) blood test in over 35,000 adults aged 50 and older with no known cancer. Among 23,161 participants with one-year follow-up, 0.93% had a positive result. The test showed high specificity (99.6%), positive predictive value (61.6%), and accurate cancer origin prediction (91.7%).

Sensitivity was 73.7% for 12 major cancers and 40.4% overall. MCED testing detected 133 cancers, over half at early stages, and most without existing screening options. With few unnecessary invasive procedures (0.6%), MCED testing increased early cancer detection.